Dose escalation and expansion study of GSK3359609 in participants with selected advanced solid tumors (INDUCE-1)

Trial Identifier: 204691
Sponsor: GlaxoSmithKline
Collaborator:
Merck Sharp & Dohme Corp.
Start Date: June 2016
Primary Completion Date: July 2023
Study Completion Date: July 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, VIC Heidelberg, VIC, Australia, 3084
Australia, VIC Melbourne, VIC, Australia, 3000
Australia, WA Nedlands, WA, Australia, 6009
Canada, ON Toronto, ON, Canada, M5G 2M9
China Shanghai, China, 200126
France Bordeaux, France, 33076
France Lyon cedex 08, France, 69373
France Paris, France, 75005
France Villejuif cedex, France, 94805
Italy Siena, Italy, 53100
Japan Chiba, Japan, 277-8577
Japan Osaka, Japan, 589-8511
Japan Tokyo, Japan, 104-0045
Netherlands AMSTERDAM, Netherlands, 1066 CX
Spain Barcelona, Spain, 08036
Spain Barcelona, Spain, 08035
Spain Madrid, Spain, 28040
Spain Malaga, Spain, 29010
Spain Sevilla, Spain, 41009
United States, CA Duarte, CA, United States, 91010
United States, CA Los Angeles, CA, United States, 90025
United States, FL Sarasota, FL, United States, 34232
United States, NY New York, NY, United States, 10016
United States, NY New York, NY, United States, 10032
United States, OK Oklahoma City, OK, United States, 73104
United States, PA Philadelphia, PA, United States, 19111
United States, TN Nashville, TN, United States, 37203
United States, TN Nashville, TN, United States, 37232-6307